Skip to main content
Erschienen in: BMC Gastroenterology 1/2023

Open Access 01.12.2023 | Matters Arising

Reply to comment on “Ultrasonographic scores for ileal Crohn’s disease assessment: better, worse or the same as contrast‑enhanced ultrasound?

verfasst von: Marta Freitas, Francisca Dias de Castro, Vítor Macedo Silva, Cátia Arieira, Tiago Cúrdia Gonçalves, Sílvia Leite, Maria João Moreira, José Cotter

Erschienen in: BMC Gastroenterology | Ausgabe 1/2023

download
DOWNLOAD
print
DRUCKEN
insite
SUCHEN

Abstract

We read the comments by Nylund K et al. regarding our paper “Ultrasonographic scores for ileal Crohn’s disease assessment: Better, worse or the same as contrast‑enhanced ultrasound?”. Intestinal ultrasound has become one of the most valuable developments in the past decade, a non-invasive, well-tolerated exam, with an easy repeatability, and absence of sedation, ionizing radiation, or preparation. Particularly for inflammatory bowel disease, where there is a lack of agreement of patient’s symptoms with disease activity, in an era where the paradigm of mucosal healing is changing to transmural healing, and with the emergence of several therapies leading to repeated imaging surveillance, it is essential to highlight the role of intestinal ultrasound. Although intestinal ultrasound is an increasingly used tool to monitor inflammatory bowel disease activity, there is no widely accepted reproducible activity index, since the methodology for the development of the scores was shown to be insufficient in most studies and none have been adequately validated (Bots et al., J Crohns Colitis 12:920–9, 2018). In our study, we showed that the contrast-enhanced ultrasound (CEUS) peak enhancement derived from the time-intensity curve (TIC) is a promising non-invasive emerging method with a good accuracy to correlate clinical and endoscopic activity in the terminal ileum, superior to intestinal ultrasound scores relying on bowel wall thickness and colour Doppler.
Hinweise

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
We read the comments by Nylund K et al. [1] regarding our paper “Ultrasonographic scores for ileal Crohn’s disease assessment: Better, worse or the same as contrast‑enhanced ultrasound?”. In fact, our study aimed to compare, in our population, the accuracy of two intestinal ultrasound scores (SUS-CD score [2] and IBUS-SAS score [3]) and CEUS in predicting inflammatory activity in the terminal ileum in ileocolonoscopy in patients with Crohn’s disease, and not creating a score.
As pointed out by the authors, we recognize that the single-center, retrospective design of our study, and the selected population are limitations. We only included patients having an intestinal ultrasound, CEUS, and endoscopy, within 1 month, explaining the small sample of the study. Although we recognize that in clinical practice this may not occur in all the situations, we only included patients with these characteristics in order to limit potential bias regarding inflammatory activity variation. Regarding the reasons for which the assessment was performed we consider that this does not influence significantly the data as we are correlating endoscopic inflammatory activity with the ultrasound findings in the same subject.
Due to the retrospective design of our study we cannot use the concept “blinded” regarding the ultrasound operator to the results of the ileocolonoscopy. However, as mentioned in the text, we guarantee that the ultrasound operator was not the same that performed ileocolonoscopy examinations and the ileocolonoscopy examinations were performed after ultrasonographic examinations by an operator that does not have experience in ultrasound. Nevertheless, we recognize that, although the operator does not perform ultrasound, as a certified gastroenterologist he is able to interpret ultrasound findings.
Regarding the SES-CD threshold used in our study for inflammation, we highlight that there is no validated optimal SES-CD cut-off score and the quantification of disease severity has likewise not been standardized yet [4]. In our study, we graded the disease activity as inactive (normal or mild disease, with a SES-CD < 7) or active (moderate or severe disease, with a SES-CD ≥ 7), based on a previous study [5]. Several studies also considered this cut-off [69]. Although, some recent papers have used SES-CD with lower cut-offs, so we admit that the cut-off that we used (SES-CD ≥ 7) could be relatively high, and a lower value might have also been justified.
The authors highlighted that CEUS bowel wall perfusion measurements for detection of inflammation is only standard of care in select centers worldwide. However, in our center, we routinely perform CEUS in Crohn’s disease patients submitted to intestinal ultrasound as a part of a regular follow-up, including suspicion of active disease, assessment of remission or relapse, and monitoring of treatment effect. We recognize that it is a recent and promising tool, that needs more investigation, and that can contribute in clinical practice to the improvement of IBD activity monitoring. Evidence for the routine use of CEUS is based on small study groups and with significant methodological heterogeneity [10], with different ultrasound scanner and CEUS quantitative software, being the major issue for standardization, so there is still a need for large prospective studies that would help introducing the method into everyday practice.
In our paper a TIC curve based on wash-in wash-out is shown, not the fitted curve and the peak intensity was manually calculated.
Finally, we did not analyze inter-rater reliability as we only included ultrasonographic examinations performed by a single expert operator to uniformize the analysis. However, we agree that this is a major point for CEUS quantitative measurements, that needs to be addressed in future studies in order to demonstrate the reproducibility, and more objective character of CEUS.

Acknowledgements

None.

Declarations

Not applicable.
Not applicable.

Competing interests

The authors declare no competing interests.
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://​creativecommons.​org/​licenses/​by/​4.​0/​. The Creative Commons Public Domain Dedication waiver (http://​creativecommons.​org/​publicdomain/​zero/​1.​0/​) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Literatur
2.
Zurück zum Zitat Sævik F, Eriksen R, Eide GE, Gilja OH, Nylund K. Development and validation of a simple ultrasound activity score for Crohn’s disease. J Crohns Colitis. 2021;15(1):115–24.CrossRefPubMed Sævik F, Eriksen R, Eide GE, Gilja OH, Nylund K. Development and validation of a simple ultrasound activity score for Crohn’s disease. J Crohns Colitis. 2021;15(1):115–24.CrossRefPubMed
3.
Zurück zum Zitat Novak KL, Nylund K, Maaser C, Petersen F, Kucharzik T, Lu C, et al. Expert consensus on optimal acquisition and development of the International Bowel Ultrasound Segmental Activity Score [IBUS-SAS]: a reliability and inter-rater variability study on intestinal ultrasonography in Crohn’s disease. J Crohns Colitis. 2021;15(4):609–16.CrossRefPubMed Novak KL, Nylund K, Maaser C, Petersen F, Kucharzik T, Lu C, et al. Expert consensus on optimal acquisition and development of the International Bowel Ultrasound Segmental Activity Score [IBUS-SAS]: a reliability and inter-rater variability study on intestinal ultrasonography in Crohn’s disease. J Crohns Colitis. 2021;15(4):609–16.CrossRefPubMed
4.
Zurück zum Zitat Klenske E, Bojarski C, Waldner M, Rath T, Neurath MF, Atreya R. Targeting mucosal healing in Crohn’s disease: what the clinician needs to know. Therap Adv Gastroenterol. 2019;12:1756284819856865.CrossRefPubMedPubMedCentral Klenske E, Bojarski C, Waldner M, Rath T, Neurath MF, Atreya R. Targeting mucosal healing in Crohn’s disease: what the clinician needs to know. Therap Adv Gastroenterol. 2019;12:1756284819856865.CrossRefPubMedPubMedCentral
5.
Zurück zum Zitat Ripollés T, Martínez MJ, Paredes JM, Blanc E, Flors L, Delgado F. Crohn disease: correlation of findings at contrast-enhanced US with severity at endoscopy. Radiology. 2009;253(1):241–8.CrossRefPubMed Ripollés T, Martínez MJ, Paredes JM, Blanc E, Flors L, Delgado F. Crohn disease: correlation of findings at contrast-enhanced US with severity at endoscopy. Radiology. 2009;253(1):241–8.CrossRefPubMed
6.
Zurück zum Zitat Moskovitz DN, Daperno M, Van Assche GA, Baert F, Gevers A, Sostegni R, et al. Defining and validating cut-offs for the simple endoscopic score for Crohn’s disease. Gastroenterology. 2007;132(4):A173-A. Moskovitz DN, Daperno M, Van Assche GA, Baert F, Gevers A, Sostegni R, et al. Defining and validating cut-offs for the simple endoscopic score for Crohn’s disease. Gastroenterology. 2007;132(4):A173-A.
7.
Zurück zum Zitat Sipponen T, Nuutinen H, Turunen U, Färkkilä M. Endoscopic evaluation of Crohn’s disease activity: comparison of the CDEIS and the SES-CD. Inflamm Bowel Dis. 2010;16(12):2131–6.CrossRefPubMed Sipponen T, Nuutinen H, Turunen U, Färkkilä M. Endoscopic evaluation of Crohn’s disease activity: comparison of the CDEIS and the SES-CD. Inflamm Bowel Dis. 2010;16(12):2131–6.CrossRefPubMed
8.
Zurück zum Zitat af Björkesten CG, Nieminen U, Turunen U, Arkkila P, Sipponen T, Färkkilä M. Surrogate markers and clinical indices, alone or combined, as indicators for endoscopic remission in anti-TNF-treated luminal Crohn’s disease. Scand J Gastroenterol. 2012;47(5):528–37.CrossRefPubMed af Björkesten CG, Nieminen U, Turunen U, Arkkila P, Sipponen T, Färkkilä M. Surrogate markers and clinical indices, alone or combined, as indicators for endoscopic remission in anti-TNF-treated luminal Crohn’s disease. Scand J Gastroenterol. 2012;47(5):528–37.CrossRefPubMed
9.
Zurück zum Zitat Algaba A, Linares PM, Fernández-Contreras ME, Ordoñez A, Trápaga J, Guerra I, et al. Relationship between levels of angiogenic and lymphangi- ogenic factors and the endoscopic, histological and clinical activity, and acute-phase reactants in patients with inflammatory bowel disease. J Crohns Colitis. 2013;7(11):e569–79.CrossRefPubMed Algaba A, Linares PM, Fernández-Contreras ME, Ordoñez A, Trápaga J, Guerra I, et al. Relationship between levels of angiogenic and lymphangi- ogenic factors and the endoscopic, histological and clinical activity, and acute-phase reactants in patients with inflammatory bowel disease. J Crohns Colitis. 2013;7(11):e569–79.CrossRefPubMed
10.
Zurück zum Zitat Serafin Z, Białecki M, Białecka A, Sconfienza LM, Kłopocka M. Contrast- enhanced ultrasound for detection of Crohn’s disease activity: systematic review and meta-analysis. J Crohns Colitis. 2016;10(3):354–62.CrossRefPubMed Serafin Z, Białecki M, Białecka A, Sconfienza LM, Kłopocka M. Contrast- enhanced ultrasound for detection of Crohn’s disease activity: systematic review and meta-analysis. J Crohns Colitis. 2016;10(3):354–62.CrossRefPubMed
Metadaten
Titel
Reply to comment on “Ultrasonographic scores for ileal Crohn’s disease assessment: better, worse or the same as contrast‑enhanced ultrasound?
verfasst von
Marta Freitas
Francisca Dias de Castro
Vítor Macedo Silva
Cátia Arieira
Tiago Cúrdia Gonçalves
Sílvia Leite
Maria João Moreira
José Cotter
Publikationsdatum
01.12.2023
Verlag
BioMed Central
Erschienen in
BMC Gastroenterology / Ausgabe 1/2023
Elektronische ISSN: 1471-230X
DOI
https://doi.org/10.1186/s12876-023-02883-4

Weitere Artikel der Ausgabe 1/2023

BMC Gastroenterology 1/2023 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Blutdrucksenkung könnte Uterusmyome verhindern

Frauen mit unbehandelter oder neu auftretender Hypertonie haben ein deutlich erhöhtes Risiko für Uterusmyome. Eine Therapie mit Antihypertensiva geht hingegen mit einer verringerten Inzidenz der gutartigen Tumoren einher.

„Jeder Fall von plötzlichem Tod muss obduziert werden!“

17.05.2024 Plötzlicher Herztod Nachrichten

Ein signifikanter Anteil der Fälle von plötzlichem Herztod ist genetisch bedingt. Um ihre Verwandten vor diesem Schicksal zu bewahren, sollten jüngere Personen, die plötzlich unerwartet versterben, ausnahmslos einer Autopsie unterzogen werden.

Hirnblutung unter DOAK und VKA ähnlich bedrohlich

17.05.2024 Direkte orale Antikoagulanzien Nachrichten

Kommt es zu einer nichttraumatischen Hirnblutung, spielt es keine große Rolle, ob die Betroffenen zuvor direkt wirksame orale Antikoagulanzien oder Marcumar bekommen haben: Die Prognose ist ähnlich schlecht.

Schlechtere Vorhofflimmern-Prognose bei kleinem linken Ventrikel

17.05.2024 Vorhofflimmern Nachrichten

Nicht nur ein vergrößerter, sondern auch ein kleiner linker Ventrikel ist bei Vorhofflimmern mit einer erhöhten Komplikationsrate assoziiert. Der Zusammenhang besteht nach Daten aus China unabhängig von anderen Risikofaktoren.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.